NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NINDS E-088-2018-1-MX-10 Amti-HERV-K Envelope Antibody and Uses Thereof MX National Stage MX/a/2019/008648 Pending
NINDS E-088-2018-1-UA-11 Amti-HERV-K Envelope Antibody and Uses Thereof UA National Stage a201909194 Pending
NHLBI E-134-2017-2-TW-01 ApoC-llA Mimetic Peptides That Antagonize ApoC-111 TW ORD 107102123 Pending
NHLBI E-134-2017-3-IN-10 APOC-II MIMETIC PEPTIDES IN National Stage 201917032726 Pending
NIA E-205-2006-2-US-26 PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE US CON 15/874,747 10308591 Issued PDF
NIA E-214-2018-0-US-01 PHENOTYPIC AGE AND DNA METHYLATION BASED BIOMARKERS FOR LIFE EXPECTANCY AND MORBIDITY US 62/618,422 Abandoned
NIAMS E-073-2011-2-US-02 ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES US DIV 15/872,592 1059-02-01 Issued PDF
NIAID E-137-2018-1-US-01 Peptide-based Vaccines, Methods Of Manufacturing, And Uses Thereof For Inducing An Immune Response US 62/617,519 Expired
NCI E-251-2015-0-US-03 OPTICAL TRAP FOR RHEOLOGICAL CHARACTERIZATION OF BIOLOGICAL MATERIALS US National Stage 15/744,672 10459212 Issued PDF
NCATS E-020-2016-0-US-08 Antifungal Compound Process US CON 15/868,784 Abandoned
NIDA E-057-2018-0-US-01 Focused Small Animal Transcranial Magnetic Stimulator US 62/616,084 Abandoned
NCATS E-257-2010-0-MX-17 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators MX DIV MX/a/2018/000385 Issued
NCI E-094-2017-0-CN-05 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment CN National Stage 201880015253.2 Issued
NCI E-094-2017-0-EP-01 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment EP DIV 21160649.6 Issued
NCI E-094-2017-0-EP-06 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment EP National Stage 18713034.9 Issued
NCI E-094-2017-0-CA-04 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment CA National Stage 3049252 Issued
NCI E-094-2017-0-AU-03 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment AU National Stage 2018205372 Issued
NCI E-094-2017-0-JP-07 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment JP National Stage 2019-537127 Issued
NIAID E-285-2002-0-US-28 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE US CON 15/866,050 10314900 Expired PDF
NCI E-094-2017-2-US-02 Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy US ORD 15/866,222 10183993 Issued PDF
NCI E-094-2017-2-PCT-01 FULLY HUMAN ANTIBODIES THAT BIND HUMAN MESOTHELIN AND METHODS OF THEIR USE PCT PCT COMB PCT/US2018/012899 Expired
NCI E-094-2017-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-MESOTHELIN IMMUNOTHERAPY PCT PCT PCT/US2018/012954 Expired
NHGRI E-031-2018-0-US-01 DETECTING PROTEIN INTERACTION SITES IN NUCLEIC ACIDS US 62/615,233 Abandoned
NIAID E-103-2014-3-US-08 Antibody Evolution Immunogens US CON 15/864,822 10849970 Issued PDF
NIAID E-120-2001-0-AU-91 Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses AU DIV 2018200091 Expired
NIAID E-006-2017-0-PCT-02 LIVE ATTENUATED FLAVIRUS VACCINES AND METHODS OF USING AND MAKING SAME PCT PCT PCT/US2018/012346 Expired
NIDA E-280-2015-0-US-01 Auto Rim-Shaped Gradient Coil US 62/613,597 Abandoned
NIAID E-154-2017-0-US-01 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE US 62/612,982 Abandoned
NIAID E-015-2017-0-PCT-02 METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES PCT PCT PCT/US2017/069024 Expired
NIA E-275-2011-0-US-16 METHOD FOR DIAGNOSING A NEURODEGENERATIVE DISEASE US CON 15/858,282 Abandoned
NIAID E-015-2017-0-EP-04 METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES EP National Stage 17835778.6 Pending
NIAID E-032-2018-0-US-01 UNIVERSAL INFLUENZA VIRUS PROBE SET FOR ENRICHMENT OF ANY INFLUENZA VIRUS NUCLEIC ACID US 62/611,734 Abandoned
NCI E-227-2017-0-US-01 EXO-CLEAN METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS US 62/612,040 Abandoned
NIAID E-015-2017-0-CA-03 METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES CA National Stage 3047132 Abandoned
NCI E-193-2015-0-US-04 METHODS OF CHARACTERIZING ADRENOCORTICAL TUMORS US National Stage 15/740,577 Abandoned
NCI E-235-2015-0-JP-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers JP National Stage 2017-567058 Abandoned
NIEHS E-292-2015-0-US-03 Methods And Composition For Treating Nephropathy US National Stage 15/739,718 Abandoned
NCI E-150-2017-2-KR-22 Diagnostic Methods For T Cell Therapy KR National Stage 10-2017-7037018 Issued
NCI E-282-2016-2-KR-27 METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY KR National Stage 10-2017-7037017 Issued
NCI E-014-2017-0-CA-04 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF CA National Stage 3045902 Issued
NCI E-014-2017-0-AU-03 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF AU National Stage 2017382883 Issued
NCI E-235-2015-0-AT-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers AT EP 16815375.7 Issued
NCI E-235-2015-0-CZ-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers CZ EP 16815375.7 Issued
NCI E-235-2015-0-IT-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers IT EP 16815375.7 Issued
NCI E-235-2015-0-GR-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers GR EP 16815375.7 Issued
NCI E-235-2015-0-IE-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers IE EP 16815375.7 Issued
NCI E-235-2015-0-HU-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers HU EP 16815375.7 Issued
NCI E-235-2015-0-SK-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers SK EP 16815375.7 Issued
NCI E-235-2015-0-SI-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers SI EP 16815375.7 Issued
NCI E-235-2015-0-CH-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers CH EP 16815375.7 Issued